Muhammad Sarki, MD
Interventional Cardiology · Mount Pleasant, WINPI 1730436817
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $11,225 of the $15,162 with a category attached, or 74.0%. Medtronic accounts for 75.3% of it on its own, with 29 other manufacturers making up the rest. 2025 is the largest year on record at $13,451, more than ten times the $160 reported in 2019.
Across 131 payments — averaging $115.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$11K
- Reflow Medical Inc$668
- Abbott$601
- Bayer$278
- Boston Scientific$247
- E.r. Squibb & Sons, L.L.C.$201
- plus $2K from 24 others
What the payments were for
- Travel & lodging$11,22574%
- Food & beverage$3,82725%
- Education$1101%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 19 | $11,421 |
| Reflow Medical Inc | 9 | $668 |
| Abbott | 5 | $601 |
| Bayer | 12 | $278 |
| Boston Scientific | 4 | $247 |
| E.r. Squibb & Sons, L.L.C. | 10 | $201 |
| Philips North America LLC | 8 | $191 |
| Boehringer Ingelheim | 4 | $148 |
| Amgen | 8 | $144 |
| Novartis | 8 | $136 |
| AstraZeneca | 3 | $134 |
| Cardiovascular Systems Inc. | 4 | $105 |
| Haemonetics Corporation | 1 | $102 |
| Cvrx, Inc. | 3 | $94 |
| Merck | 5 | $93 |
| Esperion Therapeutics, Inc. | 4 | $78 |
| Pfizer | 4 | $72 |
| Impulse Dynamics (USA) Inc. | 1 | $63 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $62 |
| Alnylam Pharmaceuticals Inc. | 2 | $51 |
| Bridgebio Pharma, Inc. | 2 | $45 |
| Heartflow, Inc. | 2 | $37 |
| Abiomed | 1 | $36 |
| Baxter Healthcare | 2 | $28 |
| W. L. Gore & Associates, Inc. | 1 | $25 |
| Biosense Webster, Inc. | 1 | $24 |
| Smith+Nephew | 1 | $22 |
| Novo Nordisk | 1 | $22 |
| Stryker | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,162 in reported general payments places this provider in the 75th percentile of 118 interventional cardiology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 124 | $115,943 |
| EliquisApixaban | 111 | $112,068 |
| EntrestoSacubitril/Valsartan | 25 | $27,480 |
| MultaqDronedarone Hcl | 12 | $22,857 |
| XareltoRivaroxaban | 18 | $19,124 |
| FarxigaDapagliflozin Propanediol | 22 | $18,251 |
| BrilintaTicagrelor | 11 | $6,753 |
| Repatha SureclickEvolocumab | 12 | $4,983 |
| Nifedipine ErNifedipine | 57 | $1,456 |
| Atorvastatin Calcium | 102 | $1,275 |
| Rosuvastatin Calcium | 79 | $1,002 |
| ClopidogrelClopidogrel Bisulfate | 54 | $911 |
| Losartan Potassium | 74 | $886 |
| Metoprolol Succinate | 100 | $879 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 36 | $794 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $148 | $115,943124 claims |
| PfizerEliquis | $72 | $112,068111 claims |
| NovartisEntresto | $136 | $27,48025 claims |
| AstraZenecaFarxiga, Brilinta | $134 | $25,00433 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 118 interventional cardiology providers in Wisconsin.
Other interventional cardiology in Mount Pleasant
- Michael SalingerMilwaukee$216K
- Arun KalyanasundaramMarshfield$201K
- Michael RosenbergManitowoc$111K
- Tanvir BajwaMilwaukee$106K
- Suhail AllaqabandMilwaukee$88K
- Saif AnwaruddinMilwaukee$80K
- Raaid MuseitifKenosha$71K
- Iyad AzzamMilwaukee$60K
- Mark HoffmannWausau$52K
- Montoya TaylorMilwaukee$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.